BlueBox Precision Medicine Fund: investing in the future of healthcare innovation
6 MAY, 2026
The healthcare sector is undergoing a profound transformation. Advances in genomics, biotechnology and data science are reshaping how diseases are understood and treated, moving away from broad therapies towards highly targeted solutions. At the centre of this shift is precision medicine – and this is exactly where the BlueBox Precision Medicine Fund is positioned.
The fund, managed by BlueBox Asset Management, which oversees more than USD 3bn in assets under management and manages a second strategy focused on technology investing, aims to deliver long-term capital growth by investing globally in companies operating across biotechnology, pharmaceuticals and life sciences. The strategy is led by co-portfolio managers Mark Dainty, MPharm, FCA and Polina Suter, PhD.
Rather than offering broad exposure to healthcare, it focuses specifically on businesses developing or enabling precision medicine.
Why precision medicine matters for investors
Precision medicine is not just a scientific evolution – it is also an economic one. Traditional drugs often fail because they do not address the underlying drivers of disease. In contrast, precision therapies are designed for specific biological targets, which increases their likelihood of success.
This shift has meaningful implications for investors. According to the fund managers’ analysis:
- Success rates in drug development can be around three times higher
- Clinical trials can be shorter and more efficient
- Development costs can be lower
- This combination has the potential to significantly enhance R&D productivity and financial returns
A focused and differentiated strategy
The BlueBox Precision Medicine Fund distinguishes itself through a high-conviction, specialist approach. It typically holds between 25 and 45 stocks and is not constrained by any benchmark, allowing the managers to focus purely on their best ideas.
The portfolio is built across the precision medicine ecosystem, combining companies that develop therapies with those that enable them. In practice, this means exposure to:
- Biotech innovators working on targeted treatments
- Life sciences tools and diagnostics companies supporting research, manufacturing and clinical use of precision medicine
- Select pharmaceutical firms aligned with the precision medicine theme
This combination helps balance growth potential with a degree of stability, as enablers tend to generate more consistent revenues and profits.
The investment process itself is deeply research-driven, integrating scientific analysis with financial evaluation. The managers focus on understanding not just individual drugs, but entire pipelines, competitive positioning and long-term business models.
Performance: strong returns, but not without volatility
Performance to 31.03.2026
| Fund / Index | 1 month | 3 months | YTD | ITD Ann |
|---|---|---|---|---|
| BlueBox Precision Medicine Fund | -6.5% | -5.9% | -5.9% | 14.2% |
| S&P BMI Healthcare Index | -8.0% | -4.4% | -4.4% | 6.3% |
12M Rolling Performance to 31 Mar.
| Fund / Index | 2026 | 2025 | 2024 |
|---|---|---|---|
| BlueBox Precision Medicine Fund | 37.5% | -13.3% | 28.9% |
| S&P BMI Healthcare Index | 6.7% | 1.7% | 12.3% |
Since its launch in February 2023, the fund has delivered strong performance relative to healthcare benchmarks. In 2025, it returned 31.3% net of fees, significantly outperforming the S&P BMI Healthcare Index.
Over the full period since inception, returns have reached around 60%, with annualised performance above 18%.
More recent figures show continued long-term strength, although short-term fluctuations remain part of the strategy. As of March 2026, the annualised return since inception stood at 14.2%, while recent months reflected the volatility typical of biotech markets.
This highlights an important point: despite being within healthcare, the fund behaves more like a growth equity strategy than a defensive allocation.
Portfolio positioning
The current portfolio reflects a clear bias towards innovation. Biotechnology represents the majority of exposure, complemented by life sciences tools and services.
Geographically, the fund is heavily weighted towards the United States, which remains the global centre of biotech innovation. Key holdings include companies such as Argenx, Vertex Pharmaceuticals and Alnylam Pharmaceuticals, alongside enablers like Natera, which provides advanced diagnostic solutions and represents a key example of the enabling segment of precision medicine.
| Company | Weight |
|---|---|
| Argenx SE | 5.6% |
| Revolution Medicines | 5.2% |
| Alnylam Pharmaceuticals | 4.5% |
| Vertex Pharmaceuticals | 4.4% |
| Apogee Therapeutics | 4.2% |
| Rhythm Pharmaceuticals | 4.2% |
| Nuvalent Inc | 4.1% |
| Natera Inc | 4.0% |
| Lonza Group | 4.0% |
| Danaher | 4.0% |
| Total | 44.2% |
This blend of developers and enablers is a core feature of the strategy, allowing the fund to capture upside from innovation while diversifying across different parts of the value chain.
| Country | Weight |
|---|---|
| United States of America | 79.5% |
| Switzerland | 6.6% |
| Belgium | 5.6% |
| France | 3.9% |
| United Kingdom | 3.1% |
| Cash & equivalents | 1.3% |
Risk profile
As with any high-growth strategy, risk is an important consideration. The fund is classified as medium-high risk, reflecting its exposure to equity markets and early-stage innovation.
Key risks include:
- Clinical trial failures or delays
- High sector volatility
- Concentration in a limited number of holdings
- Currency exposure for non-USD investors
While these risks are inherent to the sector, the fund seeks to manage them through diversification across development stages and by including revenue-generating “enabler” companies.
Final thoughts
The BlueBox Precision Medicine Fund offers a clear and differentiated proposition: targeted exposure to one of the most important long-term trends in healthcare. By focusing on precision medicine, it aligns scientific innovation with investment opportunity.
For investors willing to accept volatility in pursuit of growth, the strategy provides access to a segment of the market that is still underrepresented in traditional portfolios – but increasingly central to the future of medicine.
This is a marketing communication. Past performance is not an indication of current or future performance.
